Indo-Bangla Pharmaceuticals’ production, marketing banned | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 24, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 24, 2025
Indo-Bangla Pharmaceuticals’ production, marketing banned

Pharma

TBS Report
23 March, 2021, 10:25 pm
Last modified: 23 March, 2021, 11:43 pm

Related News

  • Indo-Bangla Pharma signs deal with Afghan firm to export medicines
  • No price-sensitive news, yet shares of Rupali Bank, Indo-Bangla Pharma, City Insurance jump
  • Stay on highest alert against activities of banned political parties: DMP
  • Bangladesh bans new industrial construction within 10km of Sundarbans
  • BSEC forms body to probe Indo-Bangla's IPO proceeds, business status

Indo-Bangla Pharmaceuticals’ production, marketing banned

On Tuesday, the company disclosed the information on the DSE and CSE websites

TBS Report
23 March, 2021, 10:25 pm
Last modified: 23 March, 2021, 11:43 pm

The drug regulatory authority has temporarily banned the production and marketing of the publicly listed company Indo-Bangla Pharmaceuticals Limited.

On Tuesday, the company disclosed the information on the Dhaka Stock Exchange (DSE) and Chittagong Stock Exchange (CSE) websites.

Company Secretary Mohi Uddin told The Business Standard, "Due to personal problems of the company authorities, the drug administration has imposed a temporary ban on our production and marketing."

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"We hope the problems will be resolved within a short time," he added.

As per information of the company, Indo-Bangla on 7 March received a letter from the Directorate General of Drug Administration (DGDA), banning the production and marketing of the company for a temporary period.

The company has instantly filed a writ petition against the order.

Acting upon the petition, the High Court on 14 March 2021 issued a rule asking the DGDA to explain why the ban on production and market should not be declared illegal.

The court fixed 6 April for the next hearing.

Previously, the name of the company was Indo-Pak Pharmaceutical Works (IPW) but after independence, the government took control of the company which was inaugurated in 1954.

It was registered in Bangladesh under the privatisation act in the name of Indo-Bangla Pharmaceutical Works.

In 1982, the government sold the company which got listed on the stock exchanges in 2018.

The company is engaged in manufacturing and selling all kinds of medicines (excluding antibiotics), and medical preparation of drugs and chemicals (human health).

The company has applied for permission for the production and selling of veterinary medicine also.

In the last fiscal year, Indo-Bangla reported a profit of Tk15.62 crore, and the earnings per share (EPS) stood at Tk1.40.

The board of the company has recommended a 4.50% cash and 2% stock dividend for the shareholders.

In fiscal 2018-2019, the company posted a profit of Tk15.52 crore and EPS was Tk1.39. It paid an 11% – 2% cash and 9% stock – dividend.

In FY20, the revenue of the company was Tk86.60 crore, which is 16.935% higher than the previous fiscal year when the revenue was Tk74.07 crore.

Corporates / Top News

Indo-Bangla Pharmaceuticals Limited / Banned / Production Banned / Marketing Banned

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BB asks female staff to wear 'modest' attire, discourages short-sleeved or length dresses, leggings
    BB asks female staff to wear 'modest' attire, discourages short-sleeved or length dresses, leggings
  • Representational image. Photo: Collected
    US yet to confirm third-round talks as tariff deadline looms
  • Govt amends public service rules further, adding appeal rights, forced retirement
    Govt amends public service rules further, adding appeal rights, forced retirement

MOST VIEWED

  • Photo: Collected
    Bangladeshi man jailed for life in UK for murdering wife in front of their baby
  • Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
    Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
  • Fire at Cosmo School in Mirpur on 23 July 2025. Photo: TBS
    Fire breaks out at Cosmo School in Mirpur following generator explosion
  • Representational image. File Photo: Rajib Dhar/TBS
    Debate arises as edu adviser says postponed HSC exams of 22 and 24 July will be held on same day
  • The Government Seal of Bangladesh
    Govt mulls allowing trade unions with 20 workers, industry leaders warn of disorder
  • Photo: CA Press Wing
    Stronger stance needed on maintaining law and order: Political parties to CA

Related News

  • Indo-Bangla Pharma signs deal with Afghan firm to export medicines
  • No price-sensitive news, yet shares of Rupali Bank, Indo-Bangla Pharma, City Insurance jump
  • Stay on highest alert against activities of banned political parties: DMP
  • Bangladesh bans new industrial construction within 10km of Sundarbans
  • BSEC forms body to probe Indo-Bangla's IPO proceeds, business status

Features

Photo: Collected

24 July: More than 1400 arrested, 3 missing coordinators found

1d | Panorama
Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

1d | Panorama
Photo: TBS

Mourning turns into outrage as Milestone students seek truth and justice

1d | Panorama
Illustration: TBS

Uttara, Jatrabari, Savar and more: The killing fields that ran red with July martyrs’ blood

2d | Panorama

More Videos from TBS

ISPR reports 31 dead, official tally 29

ISPR reports 31 dead, official tally 29

2h | TBS Today
13 political parties meet with chief advisor; urge to announce election date

13 political parties meet with chief advisor; urge to announce election date

2h | TBS Today
Bangladesh and Pakistan unite to fight drugs

Bangladesh and Pakistan unite to fight drugs

3h | TBS Today
Case Study of Milestone Tragedy

Case Study of Milestone Tragedy

4h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net